Registrations now open for the biotechnology event of the year, AusBiotech 2012
Tuesday, 08 May, 2012
AusBiotech's annual conference event has been at the heart of AusBiotech since the beginning; valued as the best way to bring together like-minded people in biotechnology to secure deals, share information and support the growth and prosperity of the industry.
AusBiotech 2012 will be held 30 October – 2 November 2012 at the Melbourne Convention & Exhibition Centre, and with the associated events is expected to attract more than 1,500 participants, as it did the last time it was held in Melbourne. The event, with the theme “realising the value”, is proudly supported by the Victorian Government.
This event saw 190 international delegates from 20 countries attend, with the largest delegations coming from New Zealand, the US, the UK, Canada and Singapore. The world-class Business Matching Program facilitated 2,947 meeting requests and 1,051 confirmed meetings.
The Australasian Life Science Investment Summit (ALSIS) 2012, is again a major satellite event that will be connected to AusBiotech 2012, and held on Friday 2 November 2012. It is the largest investment event of its kind in the Southern Hemisphere, showcasing the 40 most promising Australian biotechnology companies actively seeking capital or partnering opportunities, and last year attracted over 120 bone fide investors from around the world.
Independent research from ALSIS 2011 showed that at the end of the meeting AU$228 million worth of deals were in discussion.
AusBiotech 2012 will again feature a world-class speaking program, the ever-popular Business Matching Program, the BioIndustry Exhibition, this year with a trade afternoon, the Conference Dinner at the Peninsula in Docklands, and for the second time will present the AusFoodtech Symposium on 2 November 2012.
Check the website for the latest details: www.ausbiotechnc.org. Early bird registration is now open and AusBiotech members receive a special rate. Partnership, sponsorship and exhibition packages are available.
TGA rejects Alzheimer's drug due to safety concerns
The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...